Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Hemosol presses on with Hemolink development:

This article was originally published in Clinica

Executive Summary

Hemosol is pushing ahead with plans to resume its clinical programme in the US for its blood substitute Hemolink. The company has received FDA approval to start a key clinical trial of the product in primary heart bypass surgery. The 180-patient trial is expected to pave the way for a pivotal trial in the US and strengthen the company's regulatory application in the UK. The Toronto, Canada-based firm says it "recently redesigned its clinical programme to meet the anticipated requirements of European and US regulatory agencies".





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts